A long-acting amylin receptor agonist studied for weight management, both on its own and combined with semaglutide (a pairing known as CagriSema).
Reviewed for accuracy · Last reviewed July 8, 2026Cagrilintide mimics amylin, a hormone released alongside insulin that helps signal fullness and slow how quickly the stomach empties. It's engineered to be long-acting, which is why it has been studied as a once-weekly subcutaneous injection rather than something taken with each meal, and why researchers have paired it with the GLP-1 drug semaglutide to target appetite through two separate pathways.
It remains investigational: there is no FDA-approved cagrilintide product. The human evidence comes from a Phase 2 dose-finding obesity trial and from Phase 3 trials of the semaglutide combination (CagriSema), so every dose figure here describes what was studied rather than a prescribing guideline.
The Phase 2 obesity trial tested once-weekly subcutaneous cagrilintide at 0.3, 0.6, 1.2, 2.4, and 4.5 mg after a short escalation; the CagriSema combination uses 2.4 mg cagrilintide. Cagrilintide is investigational, so there is no approved prescribing dose.
Read the full Cagrilintide dosage guide →Across trials the most common adverse events were gastrointestinal (nausea, vomiting, diarrhea, constipation) plus injection-site reactions, generally mild to moderate and most prominent during dose escalation.
Read the full Cagrilintide side effects guide →Keep unmixed vials refrigerated and away from light. Once reconstituted, most research reports store it refrigerated for roughly 3–4 weeks. See the full storage & safety guide for handling and disposal basics.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.